AdvanCell Names Andy Porter Chief People Officer

The biotechnology company also appointed Martin Huber, M.D., to its Board of Directors.

Updated on Nov. 4, 2026 in People

AdvanCell Names Andy Porter Chief People Officer

AdvanCell appointed Andy Porter as Chief People Officer to lead its global people and information technology functions. The company also named Martin Huber, M.D., to its Board of Directors.

Why it matters

The appointments strengthen AdvanCell's executive leadership team and Board as the company advances its clinical pipeline. Huber's oncology background is positioned to guide strategy toward later-stage development.

Andy Porter brings more than 25 years of experience building and scaling biotechnology and life sciences organizations. Martin Huber brings more than three decades of oncology clinical development, regulatory and executive leadership experience.

The players

Andy Porter

Porter is a biotechnology executive with more than 25 years of experience who previously held people leadership roles at Relay Therapeutics and the Broad Institute of MIT and Harvard.

Martin Huber

Huber is an oncology executive who most recently served as President and Chief Executive Officer of Mersana Therapeutics and currently sits on the boards of Syndax Pharmaceuticals and Actuate Therapeutics.

AdvanCell

AdvanCell is a biotechnology company headquartered in Boston with operations in Brisbane, Australia, advancing a clinical pipeline.

The details

Porter will lead talent acquisition, organizational design, workforce planning, culture and employee engagement, and technology infrastructure. He previously served as Partner at HAVEN, as Chief People Officer and Chief Administrative Officer at Relay Therapeutics, and as the first Chief People Officer of the Broad Institute of MIT and Harvard.

November 4, 2026: AdvanCell announces the appointments of Andy Porter and Martin Huber.

Industry Dynamics

Porter's track record of creating dedicated Chief People Officer roles at the Broad Institute and Relay Therapeutics reflects a broader pattern of life-sciences companies formalizing people leadership as they scale. AdvanCell's move mirrors that trajectory as it advances its pipeline toward late-stage clinical work.

For Boston-area job seekers and employees, the appointment signals that AdvanCell is investing in talent acquisition and workforce planning. Changes in hiring and culture programs could affect how local life-sciences candidates approach the company.

The takeaway

Leadership changes in biotechnology often signal a company's shift toward its next development stage, and tracking hiring and board composition can offer early clues about strategic direction.